

6 January 2009 | 14 pages

# Housing Development and Infrastructure (HDIL.BO)


 Initiation of coverage 

## Initiate at Sell: High Risk-Reward Model; TDR Prices/Absorption a Concern

- Initiate at Sell, TP Rs118** — HDIL is a slum rehab specialist. We initiate at Sell/High Risk with a Rs118 target price, based on a 40% discount (factoring HDIL's high risk-reward model) to our NAV of Rs196. With high downside risk to TDR/asset prices, absorption issues in Mumbai (its domain market) given the slowdown and the stock up 61% in the last one month, we see downside risks.
- High risk-reward model** — HDIL's thrust and expertise in slum rehab projects (57% of Gross NAV) provide it with a large development opportunity that is profitable, but this high risk-reward model is not favored in a downturn.
- Mumbai airport project a big win; risks remain** — The airport project will provide HDIL with visibility and contribute Rs85/share (46% of Gross NAV). While Phase I execution is encouraging, we see correction in TDR prices/rentals, slackening demand in Mumbai and delays adversely affecting company earnings.
- Weak outlook for Mumbai a dampener** — With 89% of Gross NAV contributed by Mumbai in mostly suburban areas, we see concentration risk for HDIL. While we build in a 25% price decline factoring higher price risks, volatile capital markets and deteriorating news on leasing activity will dampen stock sentiment.
- Risks outweigh positives** — With increasing risk to TDR prices/absorption (15% of Gross NAV), slackening office demand, likely execution delays in the airport project resulting in penalties, tight liquidity crunch and the stock at a 27% discount to NAV versus our target of 40%, we believe risks outweigh positives.

<b>Sell/High Risk</b>	<b>3H</b>
Price (05 Jan 09)	Rs142.35
Target price	Rs118.00
Expected share price return	-17.1%
Expected dividend yield	1.8%
<b>Expected total return</b>	<b>-15.3%</b>
Market Cap	Rs39,216M US\$810M

### Price Performance (RIC: HDIL.BO, BB: HDIL IN)



### Statistical Abstract

Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/B	ROE	Yield
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)
2007A	5,480	22.72	367.2	6.3	4.7	119.0	0.0
2008A	14,099	51.18	125.3	2.8	1.1	64.4	2.1
2009E	10,210	37.06	-27.6	3.8	0.9	24.8	1.8
2010E	8,140	29.55	-20.3	4.8	0.7	16.4	1.8
2011E	8,956	32.51	10.0	4.4	0.6	15.6	1.8

Source: Powered by dataCentral

### Ashish Jagnani<sup>1</sup>

 +91-22-6631-9861  
 ashish.jagnani@citi.com

### Karishma Solanki<sup>1</sup>

karishma.solanki@citi.com

See Appendix A-1 for Analyst Certification and important disclosures.

Citi Investment Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

<sup>1</sup>Citigroup Global Markets India Private Limited

Fiscal year end 31-Mar	2007	2008	2009E	2010E	2011E
<b>Valuation Ratios</b>					
P/E adjusted (x)	6.3	2.8	3.8	4.8	4.4
P/E reported (x)	6.3	2.8	3.8	4.8	4.4
P/BV (x)	4.7	1.1	0.9	0.7	0.6
Dividend yield (%)	0.0	2.1	1.8	1.8	1.8
<b>Per Share Data (Rs)</b>					
EPS adjusted	22.72	51.18	37.06	29.55	32.51
EPS reported	22.72	51.18	37.06	29.55	32.51
BVPS	30.44	132.18	166.74	193.79	223.80
NAVps ordinary	na	na	na	na	na
DPS	0.00	3.00	2.50	2.50	2.50
<b>Profit &amp; Loss (RsM)</b>					
<b>Net operating income (NOI)</b>	<b>6,831</b>	<b>17,352</b>	<b>14,756</b>	<b>12,934</b>	<b>15,078</b>
G&A expenses	-211	-431	-730	-965	-1,158
Other Operating items	-13	-22	-50	-58	-66
<b>EBIT including associates</b>	<b>6,606</b>	<b>16,899</b>	<b>13,976</b>	<b>11,912</b>	<b>13,854</b>
Non-oper./net int./except.	-355	-878	-2,307	-2,609	-3,619
<b>Pre-tax profit</b>	<b>6,251</b>	<b>16,021</b>	<b>11,669</b>	<b>9,303</b>	<b>10,235</b>
Tax	-771	-1,922	-1,459	-1,163	-1,279
Extraord./Min. Int./Pref. Div.	0	0	0	0	0
<b>Reported net income</b>	<b>5,480</b>	<b>14,099</b>	<b>10,210</b>	<b>8,140</b>	<b>8,956</b>
Adjusted earnings	5,480	14,099	10,210	8,140	8,956
Adjusted EBIT	6,606	16,899	13,976	11,912	13,854
Adjusted EBITDA	6,620	16,921	14,026	11,969	13,920
<b>Growth Rates (%)</b>					
NOI	377.8	154.0	-15.0	-12.3	16.6
EBIT adjusted	394.8	155.8	-17.3	-14.8	16.3
EPS adjusted	367.2	125.3	-27.6	-20.3	10.0
<b>Cash Flow (RsM)</b>					
<b>Operating cash flow</b>	<b>-1,328</b>	<b>-39,526</b>	<b>-15,849</b>	<b>-10,678</b>	<b>-12,820</b>
Depreciation/amortization	13	22	50	58	66
Net working capital	-7,374	-53,449	-26,133	-18,875	-21,842
<b>Investing cash flow</b>	<b>-614</b>	<b>-265</b>	<b>-249</b>	<b>-273</b>	<b>-300</b>
Capital expenditure	-98	-455	-58	-63	-69
Acquisitions/disposals	0	0	0	0	0
<b>Financing cash flow</b>	<b>1,559</b>	<b>43,233</b>	<b>16,344</b>	<b>10,234</b>	<b>13,511</b>
Borrowings	1,737	27,327	17,033	10,923	14,200
Dividends paid	0	-491	-689	-689	-689
<b>Change in cash</b>	<b>-383</b>	<b>3,443</b>	<b>246</b>	<b>-717</b>	<b>391</b>
<b>Balance Sheet (RsM)</b>					
<b>Total assets</b>	<b>19,696</b>	<b>75,034</b>	<b>104,132</b>	<b>122,484</b>	<b>146,637</b>
Cash & cash equivalent	57	3,505	3,751	3,034	3,425
Net fixed assets	254	596	604	609	612
<b>Total liabilities</b>	<b>12,354</b>	<b>38,619</b>	<b>58,196</b>	<b>69,096</b>	<b>84,983</b>
Total Debt	3,757	31,127	48,160	59,083	73,283
<b>Shareholders' funds</b>	<b>7,342</b>	<b>36,415</b>	<b>45,936</b>	<b>53,388</b>	<b>61,655</b>
<b>Profitability/Solvency Ratios</b>					
EBIT margin adjusted (%)	54.9	71.0	56.5	53.9	50.2
ROE adjusted (%)	119.0	64.4	24.8	16.4	15.6
ROA adjusted (%)	39.5	29.8	11.4	7.2	6.7
Net debt to equity (%)	50.4	75.9	96.7	105.0	113.3
Interest coverage (x)	11.8	12.0	4.9	3.7	3.2

For further data queries on Citi's full coverage universe please contact CIR Data Services Asia Pacific at CIRDataServicesAsiaPacific@citi.com or +852-2501-2791



## Company Background

HDIL is part of the Wadhawan Group (founded in 1996), and among the leading slum rehab developers having rehabilitated close to 30,000 families to date – implying a potential 40% market share (excluding airport project). It has developed ~12m sq ft of SRA projects. Its expertise and past track record in execution of these projects has built up a competitive advantage for itself in this business that has high entry barriers. The company primarily operates in the Mumbai Metropolitan Region having presence across all assets, its focus being commercial and retail projects. Historically, HDIL has followed a build-sell model strategy (given thrust on SRA projects) and intends to follow the same for most of its projects. The company raised ~Rs17bn via an initial public offering (IPO) on July 2007 at Rs500/share for funding its land acquisition and ongoing slum rehab projects. Promoters control and manage the company with a 61.5% stake.

## Investment Thesis

**Sell with target price of Rs118**

We initiate coverage of HDIL with a Sell/High Risk rating and a target price of Rs118 at a 40% discount to our Mar'09E NAV of Rs196 – offering 15% downside. Given HDIL's high risk-reward model and negative sentiments for property, particularly the Mumbai market where we see significant price/absorption risk over the next 12 months, we believe risks outweigh the positives. We attribute the 40% discount to the following: 1) regulatory/political risks as HDIL's NAV is sensitive to higher FSI (Floor Space Index) norms and softening TDR/asset prices; 2) likely execution delays in the airport project resulting in penalties; 3) tight liquidity crunch; and 4) concentration risk in Mumbai suburbs (89% of Gross NAV) where price risk/supply overhang is high.

HDIL's expertise and strong track record in slum rehab projects (57% of Gross NAV) does provide the company with a competitive advantage, a large development opportunity that is highly profitable, but we believe this is a high-risk business. The airport rehab project is a big win and will provide HDIL with visibility and contribute Rs85/share (46% of our Gross NAV) to our NAV. Though the pace of Phase I execution is encouraging, we see correcting TDR prices/rentals, absorption issues and execution delays amidst deteriorating macro adversely affecting stock sentiment. A weak outlook for the Mumbai market (89% of HDIL's Gross NAV) and volatile capital markets further add to these woes. Factoring this, the company's liquidity crunch, downside risks to earnings and the stock up 61% over the last one month, risk-reward is unfavorable.

## Strategic Initiatives and Strengths

**HDIL is a market leader in slum rehab projects having completed 12m sq ft of slum rehab**

### Leverage on expertise in slum rehab – large opportunity, high entry barriers...but risky

HDIL is among the leading slum rehab developers having rehabilitated close to 30,000 families to date, implying a potential 40% market share (excluding the airport project). HDIL has developed ~12m sq ft of SRS saleable area and rehabilitation area since 1996. Its expertise in handling the slum dwellers, familiarity with the regulatory process and strong track record in execution of these projects has allowed it to build up a competitive advantage for itself in this business that has high entry barriers. The company plans to leverage on this expertise to secure marquee projects such as the Mumbai Airport project. HDIL has consciously adopted the SRS (Slum Redevelopment Scheme) route to acquire high-value, low-cost land in Mumbai. Fifty-seven percent of its Gross NAV is derived from SRS projects (~37% of landbank including the airport project). Though we see this as a large development opportunity that is highly profitable and that HDIL is best positioned to take advantage of, it is a high risk business given the downturn.

**The Mumbai Metropolitan Region accounts for 89% of HDIL's Gross NAV and 87% of its landbank**

### Mumbai the domain – a high value, high risk market today

Mumbai has huge potential for slum redevelopment given that ~2.8bn sq ft (over 1 million slums) of space is occupied by slum dwellers, of which only ~21m sq ft has been developed so far. Mumbai has traditionally been the commercial hub of India. High demand, prices and limited supply make it attractive versus other metro cities. The city has huge development potential. However, inadequate transport infrastructure, FSI constraints and dense slum population (over 1 million slums) are some of the key constraints that have historically impeded this development in Mumbai. We see higher near-term risks emerging of softening prices/rentals, supply overhang and execution delays for Mumbai's property market in this slowing environment and volatile capital markets, a key sentiment driver for Mumbai's property market. While the company has ventured into other markets such as Hyderabad, Kochi and Pune, with 87% of HDIL's landbank (196m sq ft) and 89% of Gross NAV coming out of Mumbai and its suburbs, its fortunes remain dependent on the outlook for the Mumbai market.

**Figure 1. HDIL Landbank Summary (million sq ft)**

<b>Mumbai Metropolitan Region</b>	<b>171.1</b>
-Airport TDR	53.2
-Airport Saleable Area (airport and rehab area)	14.0
-Non Airport Slum Rehab	4.6
-Residential	68.9
-Commercial & Retail	30.3
<b>Hyderabad</b>	<b>9.0</b>
<b>Kochi</b>	<b>15.0</b>
<b>Pune</b>	<b>1.2</b>
<b>Total</b>	<b>196.3</b>

Source: Company Reports, Citi Investment Research

HDIL will get 65 acres; saleable area of ~8.5m sq ft around the airport after rehabilitating slums

Phase I rehabilitation of ~22,000 families over ~59 acres in Kurla began in Jun'08; targeting completion by Dec'09

**Figure 2. Airport Project Valuation Assumptions**

Land TDR m sq ft	10
Rehab TDR m sq ft	43
Saleable Area m sq ft	14
Rental assumptions	Rs94/sq ft per mth
Saleable area FSI sales	Rs7,500/sq ft
TDR Price Range	Rs1,350-1,800/sq ft
Families	~85,000
Timeline	9 yrs
Project NAV	~Rs85/share

Source: Company Reports, CIR

**Figure 3. Recent HDIL TDR & FSI Sale Transactions**

1.5m sq ft of airport TDR and 0.15m sq ft of FSI in Bandra (w) sold in 2QFY09  
0.3m sq ft FSI sold in Santacruz project in 1QFY09  
Andheri (Kaledonia) project sold to Mack Star Marketing in 4QFY08  
Part of BKC project sold to Adani Group

Source: Company, Citi Investment Research

## Airport project a big win (46% of Gross NAV)

Given HDIL's expertise in the slum redevelopment model, MIAL (Mumbai International Airport Ltd) run by the GVK group, awarded the slum rehabilitation project to HDIL in October 2007 – a big win for the company. The agreement envisages HDIL rehabilitating ~85,000 families living in slums encroaching on 276 acres of the airport land. As per the arrangement, MIAL will use part of the freed up area to modernize and expand the existing airport; and the balance will be split for development in favor of MIAL and HDIL in a 55:45 ratio – providing HDIL with 65 acres, which converts into 8.5m sq ft saleable area assuming an FSI of 2x. Additionally, the company will be compensated via TDR (Transfer of Development Rights, similar to land rights) worth ~53m sq ft (~10m sq ft land TDRs and ~43m sq ft of construction TDRs) from government authorities for rehabilitating the slums. This apart, the project is tax exempt under the 80-IA scheme (but would be liable to the minimum alternate tax rate of ~12% versus peak rate of 34%).

## Phase I execution encouraging, but TDR/FSI absorption an issue and timely completion will be key

Both the scale and pace of construction for Phase I of HDIL's airport rehabilitation project in Kurla are encouraging. The company has started construction for Phase I (~5.5m sq ft) for rehabilitating ~22,000 families on ~59 acres in Kurla (close to the airport site), targeting to complete in 15-18 months (Dec'09). This apart, management expects to start Phase II by 1QFY10 for rehab of another ~25,000 families and targets to rehabilitate ~50,000 families by Dec'10. It has already tied-up 150 acres (of 180 acres required) for the rehab project, most of which being substantially paid. Benefiting from the recent increase in FSI to 4x on slum rehab, the company is expected to get saleable area of ~5.5m sq ft, which is also under construction along with its Phase I of rehab. It has already sold ~1.5m sq ft of land TDR available for Phase I.

While all this is encouraging; we see softening demand, sharp correction in TDR prices, absorption issues, and outstanding receivables of Rs1.5bn (as of Sept'08) on TDR sales done in 2Q as early signs of a worsening environment. Further, given social-political issues and changing regulatory norms surrounding slum rehab projects, risks of execution delays remain. However, being a critical project for the city and given the government's support, we should see timely completion of this project by FY12, otherwise HDIL will be liable to a penalty (~Rs2bn) in case of delay. We expect this project to contribute Rs85/share to our NAV estimate, factoring in saleable area of ~14m sq ft and TDR sales of ~53m sq ft (revenue recognition for TDRs to start from FY09) all to be executed by 2017 (versus management guidance of 2014). However, as a conservative measure we have not built in any additional saleable area available to the company from future phases of rehab, which could be potential upsides.

## Operates rehab/build-sell model, but asset mix geared toward commercial assets

HDIL operates on a rehab/build-sell model for most of its projects, particularly FSI in SRA projects and residential developments. This is in-line with its strategy for monetizing landbank at the earliest and getting maximum tax benefits on its SRA projects. Its plans to adopt a sale/lease approach for built-up office/retail projects (non-airport comm/retail projects are 22% of the landbank) has, however, been put on hold given the current liquidity crunch and demand slowdown.

With the company's asset mix relatively geared toward TDR/Comm/Retail (75% of Gross NAV) assets, we see higher risks to HDIL's model: 1) increasing price/rental pressures on back of softening demand in Mumbai's office/retail market and 2) supply overhang in office space building for which we have factored in a 25% price decline and execution delays.

## Risks outweigh the Positives

### Regulatory risks – likely to spoil the party

We see higher regulatory risks for HDIL given its sensitivity to policy changes on FSI norms in Mumbai. Regulatory changes proposed by the government of Maharashtra (GoM) some time back could have an adverse impact on demand and prices for TDR, directly affecting HDIL's profitability (largest TDR generator).

---

#### Figure 4. Regulatory Changes in Mumbai

Increase in rehab area (carpet) per tenement to 269 sq ft from 225 sq ft.

Increase in FSI to 4 from 2.5 for high density slum rehab projects.

Proposal to levy FSI cost (25% of ready reckoner rates) on future slum rehab projects.

Cap on space for Financial Institutions in IT Parks in Mumbai Metropolitan Region increased to 80% from 30%.

Incentive FSI to encourage earmarking of space for public parking. Additional FSI granted will be 40%-50% of the parking area.

Source: News Reports, Citi Investment Research

---

- Proposed increased FSI for suburban Mumbai from 1.0x to 1.33x and offer to sell the incremental 0.33x of FSI at a 20-70% discount to the government ready reckoner rate.
- Increase in rehab area for slum rehab projects from 225 sq ft to ~269 sq ft (carpet area) per tenement; and higher FSI from 2.5x to 4x for high density slum rehab projects likely to result in higher TDR generation.
- Proposal to levy FSI cost (25% of ready reckoner rates) on future slum rehab projects is likely to reduce the profitability of future SRA projects (we see no immediate impact on HDIL's NAV, as all projects are pre-Apr'08).

TDRs (Transferable Development Rights) are typically bought by developers to increase effective FSI from 1.0x to 2.0x. After these changes, we could see higher FSI and increased TDR generation adversely affecting demand and prices for TDRs (15% of Gross NAV) – a market HDIL dominates. As a conservative measure, we have factored average TDR prices of ~Rs1390/sq ft (versus ~Rs2300/sf in 2Q09) in HDIL's NAV, but dampened demand and regulatory changes on increasing FSI norms could adversely affect TDR prices/absorption.

### Concentration risks in Mumbai suburbs

With 87% of HDIL's landbank (196m sqft) and 89% of Gross NAV coming out of Mumbai's mostly suburban areas, we see concentration risk for HDIL. This poses risks of absorption and softening prices/rentals in the current slowing demand environment. Further, we see building supply adversely affecting the company, particularly office space in Mumbai (See Annexure 1) – this market is likely to see supply of ~29m sq ft over the next 2-3 years. While timely execution of this supply remains a challenge amidst the liquidity crunch and dampened sentiments, this will remain an overhang. Recent policy change to increase usage of non-IT space from 30% to 80% in IT-Parks in Mumbai would further add to these supply concerns and dampen rentals.

**Makes HDIL vulnerable to price, absorption and supply overhang amidst softening demand in the city**

**Figure 5. Upcoming Office Projects of Select Developers in Mumbai Metropolitan Region**

Developer	Location	Area (m sq ft)
Akruti City	Andheri, BKC, Kanjurmarg, Thane	2.45
DLF	Parel	1.90
HDIL/Mack Star Marketing	Andheri, Bhandup, Mulund, Turbhe	3.90
Indiabulls Real Estate	Parel	2.90
Kanakia	Andheri, Borivali, Rabale	1.77
Lodha Group	Kanjurmarg, Mahalaxmi	0.90
Man Infraprojects	Bandra, Nerul, Vile Parle	0.68
Marathon Realty	Mulund, Parel, Panvel	2.45
Neptune	Kurla, Mulund, Thane	2.54
Oberoi Constructions	Goregaon	0.70
Orbit Corp	Kalina, Parel, Sakinaka	0.83
Peninsula Land	Parel, Kurla	2.10
RNA	Bandra	0.15
Rustomjee	Andheri, Sion, Thane	4.98
Shree Naman Developers	BKC	0.26
<b>Total</b>		<b>28.50</b>

Source: Company Reports, ET Realty, Citi Investment Research

**High debt levels likely to lead to capital constraints raising cost of funding**

## Potential funding constraints

We see risks emerging for HDIL, as debt levels rise to Rs39b in Sep'08 vs. Rs31b in Mar'08 and Rs17b in Dec'07, on payout for land costs and construction finance need for airport rehab. With debt/equity at ~0.9x, the company's average cost of debt at 15.5% levels and pre-sales drying up over the last 2-3months, outstanding on TDR sales – we see the liquidity crunch intensifying. Although the company has managed to roll over Rs3.5bn of the short-term debt of Rs5.5bn maturing in 2HFY09, with more construction finance needed for subsequent airport rehab phases we foresee liquidity constraints continuing for a while until the demand environment improves.

## Financials

### Adopts project completion method

HDIL is among the few developers that adopt a conservative method of project completion method of accounting, under which revenue on a project is recognized only when the project is fully completed, with the risks and rewards of ownership of a unit being completely passed on to the buyer. This method of accounting is quite conservative as compared with other players in the industry, who follow a percentage of completion method. However, the reported income can be lumpy in certain years, as it recognizes projects only once completed.

### Downside risks to earnings

The key projects that are expected to be recognized over the next two years include Bandra SRS Scheme I, TDR sales in the Airport Phase I project and the Ghatkopar property. Rehabilitation work on the Bandra SRS scheme I is complete, whereas the airport project has started generating TDR from 2Q FY09. We forecast 5% revenue CAGR over FY08-11E. However, we estimate an EPS CAGR of -14% over FY08-11E due to: 1) lower margins on changing product mix and higher interest costs. That said, given the sharp deterioration in the demand outlook over the last 2-3 months, we see downside risks to earnings.

**Figure 6. HDIL Income Statement (Rs millions)**

Year to 31 Mar	FY07	FY08	FY09E	FY10E	FY11E
<b>Total Revenues</b>	<b>12,042</b>	<b>23,804</b>	<b>24,744</b>	<b>22,084</b>	<b>27,620</b>
YoY Growth (%)	177%	98%	4%	-11%	25%
<b>EBITDA</b>	<b>6,620</b>	<b>16,921</b>	<b>14,026</b>	<b>11,969</b>	<b>13,920</b>
Margin (%)	55%	71%	57%	54%	50%
Depreciation & Amortization	(13)	(22)	(50)	(58)	(66)
Other income	206	529	582	640	704
EBIT	6,812	17,428	14,558	12,552	14,559
Interest income(expense)	(561)	(1,408)	(2,890)	(3,250)	(4,324)
Profit before tax	6,251	16,021	11,669	9,303	10,235
Tax	(771)	(1,922)	(1,459)	(1,163)	(1,279)
<b>Profit after tax</b>	<b>5,480</b>	<b>14,099</b>	<b>10,210</b>	<b>8,140</b>	<b>8,956</b>

Source: Company Reports, Citi Investment Research estimates

### EBITDA Margins – likely to fluctuate

Given the conservative accounting method followed by HDIL, it is difficult to forecast margin trends. We expect margins to be in the range of 50-57% for FY09-11E; lower than FY08 margins, which were driven by one-off transaction of land sale in 4QFY08. While we expect EBITDA margins to come down as the product mix becomes more skewed toward lower-margin projects in distant suburbs, should the company choose to sell FSI in some of its slum rehab projects, margins could be higher. Rising costs, execution delays on slum rehab projects and softness in property/TDR prices if any could adversely affect margins.

### Debt levels on the rise

HDIL's debt levels have increased to Rs39b in Sep'08 versus Rs31b in Mar'08 and Rs17b in Dec'07, on payout for land costs and construction finance for Phase I airport rehab. With debt/equity already at ~0.9x and pre-sales/TDR sales down significantly, we see the liquidity crunch intensifying. Although the company has managed to roll over Rs3.5bn of the short-term debt of Rs5.5bn maturing in 2HFY09, with more construction finance needed for subsequent airport rehab phases, we foresee liquidity constraints continuing.

**HDIL debt levels are on the rise –  
concerning in current environment**



Figure 7. HDIL Balance Sheet (Rs millions)

Year to 31 Mar	FY07	FY08	FY09E	FY10E	FY11E
<b>Source of Funds</b>					
Equity Share Capital	1,800	2,143	2,755	2,755	2,755
Reserves	5,355	34,248	43,181	50,632	58,899
Net Worth	7,155	36,390	45,936	53,387	61,654
Deferred Liability	8	15	15	15	15
Minority Interest	0	1	1	1	1
Total Debt	3,757	31,127	48,160	59,083	73,283
<b>Capital Employed</b>	<b>10,920</b>	<b>67,534</b>	<b>94,112</b>	<b>112,486</b>	<b>134,953</b>
<b>Application of Funds</b>					
Gross Block	267	576	628	685	748
Depreciation	16	32	82	139	205
Net Fixed Assets	251	544	546	546	543
Capital WIP	3	52	58	63	69
Investments	1,578	1,915	2,106	2,317	2,548
Goodwill	23	91	91	91	91
Inventories	13,245	55,229	81,654	94,518	113,242
Sundry Debtors	3,113	566	742	994	1,243
Other Current Assets	1,239	13,108	15,184	20,921	25,477
Cash and Bank	57	3,505	3,751	3,034	3,425
Current Assets	17,653	72,408	101,332	119,467	143,386
Current Liabilities	(8,588)	(7,476)	(10,021)	(9,998)	(11,684)
Net Current Assets	9,065	64,933	91,311	109,469	131,702
<b>Total Net Assets</b>	<b>10,920</b>	<b>67,534</b>	<b>94,112</b>	<b>112,486</b>	<b>134,953</b>

Source: Company Reports, Citi Investment Research estimates

We see HDIL positioned as a mid-scale developer with a high risk-high reward model - thus 40% discount to NAV is fair

## Valuation

Our target price of Rs118 is based on a 40% discount to an estimated core NAV of Rs196. We see HDIL positioned as a mid-scale developer with a high risk-reward model and expect it to trade at a 40% discount to NAV, which is toward the lower end of the average discount to NAV range of 35-50% for tier-II developers. While the level of NAV discount is a matter of subjective assessment, we believe that a 40% discount is fair, given HDIL's niche positioning in the slum rehab business, visibility from the airport project and its strong track record. This is in-line with our valuation methodology for Citi's India real estate universe. We attribute the discount to the following: 1) regulatory/political risks as HDIL's NAV is sensitive to higher FSI norms and softening TDR/asset prices; 2) likely execution delays in the airport project to result in penalties; 3) tight liquidity crunch; and 4) concentration risk in Mumbai suburbs (89% of Gross NAV) where price risk/supply overhang is high.

We believe an NAV-based valuation methodology is most appropriate for developers, as NAVs value landbank, along with development across asset classes factoring in spread out time frames. Our NAV estimate of Rs196 is based on the following assumptions: 1) 25% decline in current market prices, as Mumbai being high priced faces maximum downside risk; 2) development volume of 191m sq ft (based on Mar'09); 3) an average cost of capital of 18%; and 5) a lower tax rate of 26%, factoring in tax benefits for the slum rehab and airport project. We have also provided sensitivities to further TDR/price declines and airport project delay.

**Figure 8. HDIL NAV Sensitivity**

<b>Price Change (excluding Airport TDR)</b>			
	-10%	-15%	-20%
NAV/share (Rs)	153	132	110
<b>TDR Price Change</b>			
	-10%	-15%	-20%
NAV/share (Rs)	182	174	167
<b>Delay in Airport project (TDR &amp; Saleable area)</b>			
	3 months	6 months	12 months
NAV/share (Rs)	190	184	172
<b>Cost of Capital</b>			
	15%	16%	17%
NAV/share (Rs)	236	222	209

Source: Citi Investment Research estimates

**Figure 9. HDIL NAV Summary (Rs Millions)**

Gross NAV of Residential Development	37,851
Gross NAV of Commercial Development	89,078
<b>Gross Total NAV</b>	<b>126,929</b>
Less: Amt outstanding for land	7,750
Less: Tax @ 26%	30,858
Less: Debt Outstanding	39,478
Less: Customer Advances	1,480
Add: Cash	4,016
Add: Cost of 2,300 acres acquired for Vasi-Virar SEZ	2,600
<b>Net NAV</b>	<b>53,979</b>
No. of Shares Outstanding (Millions)	275
<b>NAV Per Share (Rs)</b>	<b>196</b>

Source: Citi Investment Research estimates

The stock has significantly outperformed the Sensex by 41% and BSE Realty by 11% over the last one month. With the overall outlook for property weak, higher risks of a slowdown in Mumbai given changing regulatory norms, building supply and higher execution risks, we see downside risk for the stock from current levels.

## Risks

We rate HDIL High Risk. This is different from the Speculative Risk rating assigned by our quantitative risk rating system (which measures the stock's volatility over a 260-day period). The key reasons for our High Risk rating include: 1) encouraging progress on Phase I of airport rehab project, 2) expertise and track record in slum rehab projects, a high risk-high reward business. The main upside risks to our investment thesis and target price are 1) change in regulatory policy, favoring TDR prices, 2) more benefits/incentives offered by the government to compensate for airport rehab costs, 3) significant FSI pre-sales easing its liquidity crunch and 4) meaningful recovery in demand, particularly office space in the Mumbai market.

## Annexure 1

Figure 10. Upcoming Office Projects of Select Developers in Mumbai Metropolitan Region

Developer	Project	Location	Area (m sq ft)
Akruti City	Akruti Trade Point	Andheri	0.17
	Akruti Star	Andheri	0.35
	Akruti Sapphire	Andheri	0.30
	Akruti Iris	Andheri	0.65
	Akruti Topaz	BKC	0.06
	Akruti Corporate Park	Kanjurmarg	0.24
	Akruti SMC	Thane	0.17
	Akruti Greentech Park	Thane	0.50
DLF	NTC Mills	Parel	1.90
HDIL	Kaledonia (sold to Mack Star Marketing)	Andheri	0.55
	IT Park at Kilburn Premises	Bhandup	1.00
	IT Park and Office Space at Bombay Oxygen Premises	Mulund	0.75
	IT Park at Eveready Premises	Turbhe	1.60
Indiabulls Real Estate	Jupiter Mills	Parel	1.40
	Elphinstone Mills	Parel	1.50
Kanakia	215 Atrium	Andheri	0.30
	Western Edge - I	Borivali	0.42
	Western Edge - II & III	Borivali	0.74
	Sigma IT Park	Rabale	0.31
Lodha Group	iThink Techno Campus	Kanjurmarg	0.50
	Lodha Excelus	Mahalaxmi	0.40
Man Infraprojects	Man Mercury	Bandra	0.04
	IT Park	Nerul	0.55
	Man House	Vile Parle	0.09
Marathon Realty	Marathon Max Phase II	Mulund	0.05
	Nexzone	Panvel	2.10
	Futurex	Parel	0.30
Neptune Group	Evolution	Kurla	1.50
	Uptown	Mulund	0.04
	IT Park	Thane	1.00
Oberoi Constructions	Commerz	Goregaon	0.70
Orbit Corp	Orbit WTC	Kalina	0.33
	Hafeez Contractor House	Parel	0.23
	Business Park	Sakinaka	0.28
Peninsula Land	Peninsula Technopark	Kurla	0.90
	Peninsula Business Park	Parel	1.20
RNA	Bizz	Bandra	0.15
Rustomjee (Keystone Group)	Elita	Andheri	0.27
	Rustomjee Elita	Andheri	0.31
	Rustomjee Natraj	Andheri	0.28
	Rustomjee Aspiree	Sion	0.12
	IT Park	Thane	4.00
Shree Naman Developers	Naman Chambers	BKC	0.14
	Naman Centre	BKC	0.13
<b>Total</b>			<b>28.50</b>

Source: Company Reports, ET Realty, Citi Investment Research

# Appendix A-1

## Analyst Certification

Each research analyst(s) principally responsible for the preparation and content of all or any identified portion of this research report hereby certifies that, with respect to each issuer or security or any identified portion of the report with respect to an issuer or security that the research analyst covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each research analyst(s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this research report.

## IMPORTANT DISCLOSURES

### Housing Development and Infrastructure (HDIL.BO) Ratings and Target Price History Fundamental Research



Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Housing Development and Infrastructure in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securities-related: Housing Development and Infrastructure.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research product ("the Product"), please contact Citi Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at [www.citigroupgeo.com](http://www.citigroupgeo.com). Private Client Division clients should refer to [www.smithbarney.com/research](http://www.smithbarney.com/research). Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

### Citi Investment Research Ratings Distribution

Data current as of 31 Dec 2008

	Buy	Hold	Sell
Citi Investment Research Global Fundamental Coverage	46%	37%	17%
% of companies in each rating category that are investment banking clients	48%	43%	38%

### Guide to Fundamental Research Investment Ratings:

Citi Investment Research's stock recommendations include a risk rating and an investment rating.

**Risk ratings**, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

**Investment ratings** are a function of Citi Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

Guide to Corporate Bond Research Credit Opinions and Investment Ratings: Citi Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the

company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings. CBR risk ratings are approximately equivalent to the following matrix: Low Risk Triple A to Low Double A; Low to Medium Risk High Single A through High Triple B; Medium to High Risk Mid Triple B through High Double B; High to Speculative Risk Mid Double B and Below. The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed income security issued by a company is held to maturity, based upon both fundamental and market risk factors. Certain reports published by Citi Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk ratings. Investment ratings are a function of Citi Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight the bond is expected to outperform the relevant Citigroup bond market sector index (Broad Investment Grade, High Yield Market or Emerging Market), performances of which are updated monthly and can be viewed at <http://sd.ny.smb.com/> using the "Indexes" tab; Hold/Neutral Weight the bond is expected to perform in line with the relevant Citigroup bond market sector index; or Sell/Underweight the bond is expected to underperform the relevant sector of the Citigroup indexes.

---

## **OTHER DISCLOSURES**

The subject company's share price set out on the front page of this Product is quoted as at 05 January 2009 04:00 PM on the issuer's primary market.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citi Smith Barney Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product is made available in France by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in Italy by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Foro Buonaparte

16, Milan, 20121, Italy. If the Product was prepared by Citi Investment Research and distributed in Japan by Nikko Citigroup Limited ("NCL"), it is being so distributed under license. If the Product was prepared by NCL and distributed by Nikko Cordial Securities Inc. or Citigroup Global Markets Inc. it is being so distributed under license. NCL is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. In the event that an error is found in an NCL research report, a revised version will be posted on Citi Investment Research's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd. (Company Number 604457), a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 Lambton Quay, Wellington. The Product is made available in Pakistan by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Spain by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in Taiwan through Citigroup Global Markets Taiwan Securities Company Ltd., which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in Turkey through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. The Product is made available in U.A.E. by Citigroup Global Markets Limited, which is authorised and regulated by the Dubai Financial Services Authority. DIFC, Bldg 2, Level 7, PO Box 506560, Dubai, UAE. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Investment Research's Products can be found at [www.citigroupgeo.com](http://www.citigroupgeo.com). Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

---

© 2009 Citigroup Global Markets Inc. (© Nikko Citigroup Limited, if this Product was prepared by it). Citi Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc and its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

---

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST